Human pregnane X receptor and sexual dimorphism in alcoholic liver disease

Information

  • Research Project
  • 10265520
  • ApplicationId
    10265520
  • Core Project Number
    R01AA028806
  • Full Project Number
    5R01AA028806-02
  • Serial Number
    028806
  • FOA Number
    PA-17-297
  • Sub Project Id
  • Project Start Date
    9/20/2020 - 4 years ago
  • Project End Date
    6/30/2025 - 4 months from now
  • Program Officer Name
    RADAEVA, SVETLANA
  • Budget Start Date
    7/1/2021 - 3 years ago
  • Budget End Date
    6/30/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    02
  • Suffix
  • Award Notice Date
    7/2/2021 - 3 years ago

Human pregnane X receptor and sexual dimorphism in alcoholic liver disease

Title: Human pregnane X receptor and sexual dimorphism in alcoholic liver disease. Abstract: Alcoholic liver disease (ALD) develops from excessive alcohol use and is more severe in both human and rodent females than their male counterparts. Female alcoholics also have higher death rate than men. Several mechanisms have been proposed to account for more severe ALD in females, including sex differences in ethanol (EtOH) pharmacokinetics, estrogen levels, and alcohol elimination rates. However, the precise mechanism(s) is/are not well understood, although there are recent indications that suggest complexities in both ALD sexual dimorphism and ALD pathogenesis. For example, the upregulation of murine hepatic fat-specific protein 27 (Fsp27) and its human ortholog, cell death-inducing DNA fragmentation factor alpha-like effector c (CIDEC), which have been previously implicated in metabolic disorders and cell apoptosis, promote a progressive form of ALD, alcoholic steatohepatitis (ASH) in both mice and human patients with ASH. However, whether EtOH hepatotoxicity in females involves Fsp27 upregulation is unknown. FSP27 is a target gene of the lipogenic transcription factor peroxisome proliferator-activated receptor ? (PPAR?) and inhibition of PPAR? ameliorates ASH in mice. Upstream, PPAR? is transcriptionally regulated by pregnane X receptor (PXR), a xenobiotic nuclear receptor that induces genes involved in the detoxification of drugs and other foreign chemicals. We have previously shown that mouse PXR exacerbates EtOH-induced hepatotoxicity. Therefore, we asked whether human PXR signaling similarly modulates the PPAR?-FSP27 signaling axis in EtOH hepatotoxicity, particularly, focusing on sex differences in ALD. Unexpectedly, we found that chronic-plus-binge EtOH ingestion upregulated both PPAR? and FSP27 in a sex-dependent manner in a PXR-humanized (hPXR) mice, lacking the mouse Pxr gene, but carrying the full human PXR gene. Furthermore, the nuclear constitutive androstane receptor (CAR) and PXR target gene, Cyp2b10, known to generate reactive oxygen species, was also increased in the livers of EtOH-fed female hPXR mice. Thus, our central hypothesis is that the female hPXR gene mediates sexual dimorphism in EtOH hepatotoxicity via increased lipogenesis and synergistic generation of reactive oxygen species (ROS) by enhanced Fsp27 and Cyp2b10 gene expression. To address these hypotheses, we will determine the contribution of the PXR-PPAR?-FSP27 signaling axis to female-specific ALD pathology (Aim 1). determine whether CYP2B6 induction is involved in female-specific EtOH-induced hepatotoxicity (Aim 2). determine the contribution of PXR, PPAR?, CYP2B6, and CIDEC genetic polymorphisms to sex and ethnic differences in ALD (Aim 3). A strength of this proposal is that, it makes use of humanized mice and human tissues from both sexes, expediting application to clinical studies. Based on our strong preliminary data, this proposal will provide valuable insights into how sex and species-specific regulation of PXR target genes, as well as specific biomarkers from metabolomics contribute to sex difference in EtOH-induced hepatotoxicity, which may identify therapeutic targets for the treatment of ALD.

IC Name
NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM
  • Activity
    R01
  • Administering IC
    AA
  • Application Type
    5
  • Direct Cost Amount
    225000
  • Indirect Cost Amount
    108000
  • Total Cost
    333000
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    273
  • Ed Inst. Type
    ORGANIZED RESEARCH UNITS
  • Funding ICs
    NIAAA:333000\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    XNDA
  • Study Section Name
    Xenobiotic and Nutrient Disposition and Action Study Section
  • Organization Name
    NORTH CAROLINA CENTRAL UNIVERSITY
  • Organization Department
    NONE
  • Organization DUNS
    783691801
  • Organization City
    DURHAM
  • Organization State
    NC
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    277073129
  • Organization District
    UNITED STATES